CARTITUDE-2: Cilta-cel ± Len maintenance for MM with suboptimal response to ASCT
The Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, ES. We asked about the latest findings from the updated follow-up of CARTITUDE-2 Cohort D.
During this interview, Mateos discussed the latest outcomes from the phase II CARTITUDE-2, multicohort study evaluating ciltacabtagene autoleucel (Cilta-cel) across various clinical settings of unmet need. She covered the updated follow-up data (40.2 months) from Cohort D from the trial, as presented at the 22nd IMS Annual Meeting (September, 17–20, 2025), investigating Cilta-cel + lenalidomide (Len) maintenance…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.